An expert statment on clinical considerations before treating NTM lung infection
R. Chiron (Montpellier Cedex 5, France), N. Veziris (Paris, France), C. Andrejak (Amiens, France), W. Hoefsloot (Nijmegen, Netherlands), Z. Aoun (Beirut, Lebanon), C. Audoly (Marseille, France), D. Basille (Amiens, France), A. Benattia (Paris, France), A. Bergeron (Paris, France), J. Bervar (Lille, France), J. Boitiaux (Pontoise, France), A. Bourdin (Montpellier, France), D. Bouvry (Paris, France), J. Cadranel (Paris, France), G. Chatté (Caluire, France), L. Colombain (Perpignan, France), J. Couderc (Suresnes, France), B. Crestani (Paris, France), J. Crouzet (Nimes, France), G. Deslee (Reims, France), B. Douvry (Créteil, France), M. Drevait (Montpellier, France), M. Dupuy Grasset (Limoges, France), S. Jouneau (Rennes, France), M. Kerjouan (Rennes, France), S. Leroy (Nice, France), T. Maitre (Paris, France), J. Mallet (Montpellier, France), M. Massongo (Yaounde, Cameroon), M. Murris Espin (Toulouse, France), A. Payet (La Réunion, France), P. Pradère (Clamart, France), A. Prevotat (Lille, France), C. Rogé (Morlaix, France), F. Schlemmer (Paris, France), L. Slim (Ariana, Tunisia), C. Toper (Saint Cloud, France), F. Tritar (Ariana, Tunisia), M. Patrizi (Paris AP HP, France), V. Bouix (Alès, France), F. Blanc (Nantes, France), E. Catherinot (Suresnes, France)
Source: Virtual Congress 2020 – Aspergillosis and chronic lung infections
Session: Aspergillosis and chronic lung infections
Session type: E-poster session
Number: 2315
Disease area: Respiratory infections
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. Chiron (Montpellier Cedex 5, France), N. Veziris (Paris, France), C. Andrejak (Amiens, France), W. Hoefsloot (Nijmegen, Netherlands), Z. Aoun (Beirut, Lebanon), C. Audoly (Marseille, France), D. Basille (Amiens, France), A. Benattia (Paris, France), A. Bergeron (Paris, France), J. Bervar (Lille, France), J. Boitiaux (Pontoise, France), A. Bourdin (Montpellier, France), D. Bouvry (Paris, France), J. Cadranel (Paris, France), G. Chatté (Caluire, France), L. Colombain (Perpignan, France), J. Couderc (Suresnes, France), B. Crestani (Paris, France), J. Crouzet (Nimes, France), G. Deslee (Reims, France), B. Douvry (Créteil, France), M. Drevait (Montpellier, France), M. Dupuy Grasset (Limoges, France), S. Jouneau (Rennes, France), M. Kerjouan (Rennes, France), S. Leroy (Nice, France), T. Maitre (Paris, France), J. Mallet (Montpellier, France), M. Massongo (Yaounde, Cameroon), M. Murris Espin (Toulouse, France), A. Payet (La Réunion, France), P. Pradère (Clamart, France), A. Prevotat (Lille, France), C. Rogé (Morlaix, France), F. Schlemmer (Paris, France), L. Slim (Ariana, Tunisia), C. Toper (Saint Cloud, France), F. Tritar (Ariana, Tunisia), M. Patrizi (Paris AP HP, France), V. Bouix (Alès, France), F. Blanc (Nantes, France), E. Catherinot (Suresnes, France). An expert statment on clinical considerations before treating NTM lung infection. 2315
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: